Showing results (1171-1180 of 3,351) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|February 17, 2018
Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?Fernando Antoñanzas, Roberto Rodríguez-Ibeas, Carmelo A Juárez-CastellóPharmacoeconomics|March 10, 2018
New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and OutcomesAlice Varnava, Robert Bracchi, Karen Samuels, et al.Pharmacoeconomics|June 20, 2016
Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UKJamie Elvidge, Ash Bullement, Anthony J HatswellPharmacoeconomics|January 19, 2023
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?R Brett McQueen, Kelly E Anderson, Joseph F Levy, et al.Pharmacoeconomics|November 10, 2001
Impact of allergic rhinitis treatment on quality of lifeA Tripathi, R PattersonPharmacoeconomics|November 10, 2001
Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trialM Ekman, N Zethraeus, B JönssonPharmacoeconomics|November 10, 2001
Different approaches to valuing the lost productivity of patients with migraineJ H Lofland, J C Locklear, K D FrickPharmacoeconomics|November 10, 2001
Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspectiveS E Sinclair, L Frighetto, P S Loewen, et al.Pharmacoeconomics|November 10, 2001
A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapyG Dranitsaris, P Leung, R Ciotti, et al.Pharmacoeconomics|November 10, 2001
Using health outcomes data to inform decision-making: healthcare payer perspectiveP J Lancry, R Oconnor, D Stempel, et al.Pageof 336